Vicki Morrison

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011
    V A Morrison
    Section of Hematology Oncology and Infectious Disease, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 19:3611-21. 2001
  2. ncbi request reprint Myeloid growth factors: to use or not to use, that is the question
    Vicki Morrison
    University of Minnesota, USA
    Leuk Lymphoma 47:780-2. 2006
  3. ncbi request reprint Caspofungin: an overview
    Vicki A Morrison
    University of Minnesota, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Expert Rev Anti Infect Ther 3:697-705. 2005
  4. ncbi request reprint The role of caspofungin and the echinocandins in the antifungal armamentarium
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affirs Medical Center, Minneapolis, MN 55417 USA
    Curr Opin Investig Drugs 3:1432-6. 2002
  5. ncbi request reprint Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 20:3878-84. 2002
  6. ncbi request reprint Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia
    V A Morrison
    University of Minnesota, Sections of Hematology Oncology and Infectious Disease, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Expert Rev Anticancer Ther 1:84-90. 2001
  7. ncbi request reprint The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis
    V A Morrison
    Veterans Affairs Medical Center, Minneapolis, MN
    Clin Lymphoma 2:47-56. 2001
  8. ncbi request reprint Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
    Robert E Martell
    Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 50:37-45. 2002
  9. ncbi request reprint Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas
    Vicki A Morrison
    University of Minnesota, Hematology Oncology and Infectious Disease, VA Medical Center, Minneapolis, Minnesota 55471, USA
    Oncology (Williston Park) 21:1191-8; discussion 1198-1208, 1210. 2007
  10. ncbi request reprint Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma
    Vicki A Morrison
    University of Minnesota, Minneapolis 55471, USA
    Oncology (Williston Park) 21:1104-10. 2007

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011
    V A Morrison
    Section of Hematology Oncology and Infectious Disease, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 19:3611-21. 2001
    ....
  2. ncbi request reprint Myeloid growth factors: to use or not to use, that is the question
    Vicki Morrison
    University of Minnesota, USA
    Leuk Lymphoma 47:780-2. 2006
  3. ncbi request reprint Caspofungin: an overview
    Vicki A Morrison
    University of Minnesota, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Expert Rev Anti Infect Ther 3:697-705. 2005
    ..Caspofungin may be considered as a component of combination antifungal regimens. Caspofungin represents a significant advance in the care of patients with serious fungal infections...
  4. ncbi request reprint The role of caspofungin and the echinocandins in the antifungal armamentarium
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affirs Medical Center, Minneapolis, MN 55417 USA
    Curr Opin Investig Drugs 3:1432-6. 2002
    ..Concomitant use of this agent with cyclosporine is presently not recommended. Other echinocandin derivatives presently in phase II/III clinical development include micafungin and anidulafungin...
  5. ncbi request reprint Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 20:3878-84. 2002
    ..A series of patients enrolled onto an intergroup CLL trial were examined for this complication...
  6. ncbi request reprint Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia
    V A Morrison
    University of Minnesota, Sections of Hematology Oncology and Infectious Disease, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Expert Rev Anticancer Ther 1:84-90. 2001
    ..We will review the pathogenesis of infection, spectrum of infections, risk factors for infection and approaches for infection prophylaxis and therapy...
  7. ncbi request reprint The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis
    V A Morrison
    Veterans Affairs Medical Center, Minneapolis, MN
    Clin Lymphoma 2:47-56. 2001
    ..Prospective clinical trials examining supportive care measures, such as colony-stimulating factor, for elderly NHL patients are recommended...
  8. ncbi request reprint Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
    Robert E Martell
    Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 50:37-45. 2002
    ..We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL...
  9. ncbi request reprint Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas
    Vicki A Morrison
    University of Minnesota, Hematology Oncology and Infectious Disease, VA Medical Center, Minneapolis, Minnesota 55471, USA
    Oncology (Williston Park) 21:1191-8; discussion 1198-1208, 1210. 2007
    ..The disease incidence and treatment approaches for both follicular (part 1) and diffuse aggressive (part 2) histologies in elderly patients are reviewed, as well as the impact of aging on the care of these patients...
  10. ncbi request reprint Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma
    Vicki A Morrison
    University of Minnesota, Minneapolis 55471, USA
    Oncology (Williston Park) 21:1104-10. 2007
    ..The disease incidence and treatment approaches for both follicular (part 1 of this article) and diffuse aggressive (part 2) histologies in elderly patients are reviewed, as well as the impact of aging on the care of these patients...
  11. ncbi request reprint Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices
    Vicki A Morrison
    Hematology Oncology, VA Medical Center, Minneapolis, MN 55417, USA
    J Manag Care Pharm 13:337-48. 2007
    ....
  12. ncbi request reprint International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature
    Stuart M Lichtman
    Memorial Sloan Kettering Cancer Center, Commack, New York 11725, USA
    J Clin Oncol 25:1832-43. 2007
    ..In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient...
  13. ncbi request reprint Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
    ....
  14. ncbi request reprint Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 101:6-14. 2003
    ..Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted...
  15. ncbi request reprint Echinocandin antifungals: review and update
    Vicki A Morrison
    Hematology Oncology and Infectious Disease, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN 55417, USA
    Expert Rev Anti Infect Ther 4:325-42. 2006
    ..The echinocandins are an important addition to the antifungal armamentarium in the treatment of fungal infections in both immunocompromised patients and those with normal immunity...
  16. ncbi request reprint Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial
    Anne H Blaes
    Department of Medicine, The University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer 104:1661-7. 2005
    ..Alternative treatments such as rituximab have been explored...
  17. ncbi request reprint Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:49-53. 2005
    ..Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine...
  18. ncbi request reprint Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Leuk Lymphoma 44:2069-76. 2003
    ..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...
  19. ncbi request reprint Infectious complications of chronic lymphocytic leukemia
    Punit D Wadhwa
    Section of Hematology Oncology, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN 55417, USA
    Semin Oncol 33:240-9. 2006
    ....
  20. ncbi request reprint Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study
    Alice B Kornblith
    Breast Oncology Program, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 107:2706-14. 2006
    ....
  21. ncbi request reprint Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients
    Balkrishna N Jahagirdar
    Section of Hematology, Oncology, and Transplantation, University of Minnesota, USA
    Semin Respir Infect 17:113-20. 2002
    ....
  22. doi request reprint Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  23. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...